{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:14:52Z","timestamp":1791918892003,"version":"4.3.4"},"reference-count":246,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01-AG057522"],"award-info":[{"award-number":["R01-AG057522"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS113548-A1"],"award-info":[{"award-number":["R01-NS113548-A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ymthe.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T09:48:34Z","timestamp":1610444914000},"page":"949-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-4675","authenticated-orcid":false,"given":"Gabriella","family":"MacDougall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan Y.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornit","family":"Chiba-Falek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.01.001_bib1","series-title":"World Alzheimer Report 2015 The Global Impact of Dementia An Analysis of Prevalence, Incidence, Cost and Trends","author":"Prince","year":"2015"},{"key":"10.1016\/j.ymthe.2021.01.001_bib2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Murray","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.01.001_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.64.9.1242","article-title":"The relationship of Parkinson disease with aging","volume":"64","author":"Levy","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010-2050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2021.01.001_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s Disease Facts and Figures","volume":"16","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2021.01.001_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","article-title":"The worldwide costs of dementia 2015 and comparisons with 2010","volume":"13","author":"Wimo","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2021.01.001_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ymthe.2021.01.001_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570159X14666151120123025","article-title":"Current Pharmaceutical Treatments and Alternative Therapies of Parkinson\u2019s Disease","volume":"14","author":"Dong","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib10","doi-asserted-by":"crossref","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018","article-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects.","author":"Stoker","year":"2018"},{"key":"10.1016\/j.ymthe.2021.01.001_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12929-017-0355-7","article-title":"Drug candidates in clinical trials for Alzheimer\u2019s disease","volume":"24","author":"Hung","year":"2017","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease Modification in Parkinson\u2019s Disease: Current Approaches, Challenges, and Future Considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2021.01.001_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib14","first-page":"5380346","article-title":"Clinical Trials in Alzheimer\u2019s Disease: A Hurdle in the Path of Remedy","volume":"2020","author":"Oxford","year":"2020","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib15","doi-asserted-by":"crossref","first-page":"a006320","DOI":"10.1101\/cshperspect.a006320","article-title":"Animal models of Alzheimer disease","volume":"2","author":"LaFerla","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2021.01.001_bib17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tins.2006.06.010","article-title":"Inducible proteopathies","volume":"29","author":"Walker","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-013-0234-1","article-title":"Animal models of Parkinson\u2019s disease: a gateway to therapeutics?","volume":"11","author":"Le","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2021.01.001_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/ijmm.2015.2428","article-title":"Experimental models of Alzheimer\u2019s disease for deciphering the pathogenesis and therapeutic screening (Review)","volume":"37","author":"Li","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib21","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2021.01.001_bib22","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/msj.20159","article-title":"Transgenic mouse models of Alzheimer\u2019s disease","volume":"77","author":"Elder","year":"2010","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2014.05.041","article-title":"Alzheimer\u2019s disease genetics: from the bench to the clinic","volume":"83","author":"Karch","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib31","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.1523\/JNEUROSCI.20-17-06452.2000","article-title":"Aging increased amyloid peptide and caused amyloid plaques in brain of old APP\/V717I transgenic mice by a different mechanism than mutant presenilin1","volume":"20","author":"Dewachter","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.neurobiolaging.2003.09.008","article-title":"APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1","volume":"25","author":"Jankowsky","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2021.01.001_bib33","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1523\/JNEUROSCI.23-26-08989.2003","article-title":"PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation","volume":"23","author":"Richards","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1471-4159.2003.01879.x","article-title":"Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms","volume":"86","author":"Andorfer","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","article-title":"Alzheimer\u2019s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits","volume":"169","author":"Schindowski","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib25","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1074\/jbc.274.10.6483","article-title":"Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain","volume":"274","author":"Moechars","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.01.001_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/27351","article-title":"Neuron loss in APP transgenic mice","volume":"395","author":"Calhoun","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib28","doi-asserted-by":"crossref","first-page":"13287","DOI":"10.1073\/pnas.94.24.13287","article-title":"Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology","volume":"94","author":"Sturchler-Pierrat","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib29","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","article-title":"High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation","volume":"20","author":"Mucke","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib30","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.1074\/jbc.M010977200","article-title":"Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation","volume":"276","author":"Schneider","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0197-4580(02)00091-X","article-title":"Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice","volume":"24","author":"Gomez-Isla","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2021.01.001_bib39","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","article-title":"Human alpha-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53--> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice","volume":"99","author":"Lee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib40","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1074\/jbc.RA118.006551","article-title":"E46K-like \u03b1-synuclein mutants increase lipid interactions and disrupt membrane selectivity","volume":"294","author":"Rovere","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"issue":"Pt B","key":"10.1016\/j.ymthe.2021.01.001_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jchemneu.2016.01.007","article-title":"LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity","volume":"76","author":"Karuppagounder","year":"2016","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.ymthe.2021.01.001_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5607\/en.2019.28.4.504","article-title":"HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice","volume":"28","author":"Kim","year":"2019","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nbd.2018.08.018","article-title":"G2019S LRRK2 mutation facilitates \u03b1-synuclein neuropathology in aged mice","volume":"120","author":"Novello","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib45","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1073\/pnas.1712648115","article-title":"Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice","volume":"115","author":"Xiong","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib46","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/hmg\/ddn115","article-title":"The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells","volume":"17","author":"Kyratzi","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neuint.2006.07.015","article-title":"Dopaminergic neuronal loss in transgenic mice expressing the Parkinson\u2019s disease-associated UCH-L1 I93M mutant","volume":"50","author":"Setsuie","year":"2007","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ymthe.2021.01.001_bib48","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/hmg\/ddg239","article-title":"Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse","volume":"12","author":"Itier","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib49","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1074\/jbc.M401135200","article-title":"Mitochondrial dysfunction and oxidative damage in parkin-deficient mice","volume":"279","author":"Palacino","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib50","doi-asserted-by":"crossref","first-page":"e5777","DOI":"10.1371\/journal.pone.0005777","article-title":"Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration","volume":"4","author":"Gispert","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.neuron.2005.01.041","article-title":"Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1","volume":"45","author":"Goldberg","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib54","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","article-title":"Apolipoprotein E as a Therapeutic Target in Alzheimer\u2019s Disease: A Review of Basic Research and Clinical Evidence","volume":"30","author":"Yamazaki","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ymthe.2021.01.001_bib55","doi-asserted-by":"crossref","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","article-title":"APOE4-specific changes in A\u03b2 accumulation in a new transgenic mouse model of Alzheimer disease","volume":"287","author":"Youmans","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib57","doi-asserted-by":"crossref","first-page":"e12038","DOI":"10.1002\/trc2.12038","article-title":"Improving preclinical to clinical translation in Alzheimer\u2019s disease research","volume":"6","author":"Sukoff Rizzo","year":"2020","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"10.1016\/j.ymthe.2021.01.001_bib58","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms17091447","article-title":"Toxin-Induced Experimental Models of Learning and Memory Impairment","volume":"17","author":"More","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib87","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","article-title":"Revisiting the cholinergic hypothesis in the development of Alzheimer\u2019s disease","volume":"35","author":"Craig","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ymthe.2021.01.001_bib88","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2000.2.3\/cgilles","article-title":"Pharmacological models in Alzheimer\u2019s disease research","volume":"2","author":"Gilles","year":"2000","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-319-60189-2_9","article-title":"Aluminum and Alzheimer\u2019s Disease","volume":"18","author":"Colomina","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib66","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jmb.2019.01.018","article-title":"Metal Toxicity Links to Alzheimer\u2019s Disease and Neuroinflammation","volume":"431","author":"Huat","year":"2019","journal-title":"J.\u00a0Mol. Biol."},{"issue":"s1","key":"10.1016\/j.ymthe.2021.01.001_bib67","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.3233\/JAD-179944","article-title":"Iron and Alzheimer\u2019s Disease: An Update on Emerging Mechanisms","volume":"64","author":"Lane","year":"2018","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib68","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.tips.2018.10.001","article-title":"Copper and Zinc Dysregulation in Alzheimer\u2019s Disease","volume":"39","author":"Sensi","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.pnpbp.2004.12.008","article-title":"Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging","volume":"29","author":"Araujo","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ymthe.2021.01.001_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FBP.0b013e32832c70f5","article-title":"Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity","volume":"20","author":"Hodges","year":"2009","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib61","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.neubiorev.2010.04.001","article-title":"The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies","volume":"34","author":"Klinkenberg","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ymthe.2021.01.001_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuro.2013.05.002","article-title":"Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer\u2019s disease pathology","volume":"37","author":"Kamat","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2021.01.001_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuroscience.2013.01.075","article-title":"Okadaic acid-induced Tau phosphorylation in rat brain: role of NMDA receptor","volume":"238","author":"Kamat","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2021.01.001_bib64","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12640-019-0005-9","article-title":"Okadaic Acid and Hypoxia Induced Dementia Model of Alzheimer\u2019s Type in Rats","volume":"35","author":"Kaushal","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ymthe.2021.01.001_bib69","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","article-title":"Animal models of Parkinson\u2019s disease","volume":"279","author":"Blandini","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2021.01.001_bib70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.nrl.2015.06.011","article-title":"The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model","volume":"32","author":"Hernandez-Baltazar","year":"2017","journal-title":"Neurologia"},{"key":"10.1016\/j.ymthe.2021.01.001_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.33549\/physiolres.933895","article-title":"In\u00a0vivo, in\u00a0vitro and pharmacologic models of Parkinson\u2019s disease","volume":"68","author":"Salari","year":"2019","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ymthe.2021.01.001_bib72","first-page":"3234","article-title":"Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson\u2019s disease","volume":"14","author":"Thiele","year":"2012","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.ymthe.2021.01.001_bib73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2011.03.015","article-title":"Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"182","author":"Goldberg","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2021.01.001_bib74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF03159727","article-title":"Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse","volume":"10","author":"Heikkila","year":"1989","journal-title":"Mol. Chem. Neuropathol."},{"issue":"Suppl","key":"10.1016\/j.ymthe.2021.01.001_bib75","doi-asserted-by":"crossref","first-page":"299S","DOI":"10.1016\/0197-0186(92)90256-Q","article-title":"The MPTP-treated mouse as a model of parkinsonism: how good is it?","volume":"20","author":"Heikkila","year":"1992","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ymthe.2021.01.001_bib76","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neures.2017.11.008","article-title":"Mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of mice with MPTP-induced Parkinson\u2019s disease","volume":"132","author":"Kusuda","year":"2018","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ymthe.2021.01.001_bib77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neulet.2008.10.070","article-title":"Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse","volume":"448","author":"Liu","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2021.01.001_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neuro.2014.12.002","article-title":"An update on the rotenone models of Parkinson\u2019s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions","volume":"46","author":"Johnson","year":"2015","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2021.01.001_bib79","doi-asserted-by":"crossref","first-page":"e8762","DOI":"10.1371\/journal.pone.0008762","article-title":"Progression of Parkinson\u2019s disease pathology is reproduced by intragastric administration of rotenone in mice","volume":"5","author":"Pan-Montojo","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib80","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1289\/ehp.1002839","article-title":"Rotenone, paraquat, and Parkinson\u2019s disease","volume":"119","author":"Tanner","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.ymthe.2021.01.001_bib81","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s12035-018-1148-z","article-title":"Revisiting the Paraquat-Induced Sporadic Parkinson\u2019s Disease-Like Model","volume":"56","author":"Bast\u00edas-Candia","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib82","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neuro.2006.05.012","article-title":"Paraquat exposure as an etiological factor of Parkinson\u2019s disease","volume":"27","author":"Dinis-Oliveira","year":"2006","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymthe.2021.01.001_bib83","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/19338244.2018.1492894","article-title":"Paraquat exposure and Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"74","author":"Tangamornsuksan","year":"2019","journal-title":"Arch. Environ. Occup. Health"},{"key":"10.1016\/j.ymthe.2021.01.001_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yrtph.2018.05.005","article-title":"Pesticide exposure and risk of Parkinson\u2019s disease: Dose-response meta-analysis of observational studies","volume":"96","author":"Yan","year":"2018","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","article-title":"Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration","volume":"82","author":"Paumier","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib86","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson\u2019s Disease in Rodents","volume":"8","author":"Polinski","year":"2018","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib89","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ymthe.2021.01.001_bib90","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mcp.2016.11.001","article-title":"Genetics of Parkinson\u2019s disease","volume":"30","author":"Lill","year":"2016","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.ymthe.2021.01.001_bib91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainresbull.2011.07.019","article-title":"Genetically engineered mouse models of Parkinson\u2019s disease","volume":"88","author":"Crabtree","year":"2012","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ymthe.2021.01.001_bib92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","article-title":"Genetic animal models of Parkinson\u2019s disease","volume":"66","author":"Dawson","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib93","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10048-018-0546-8","article-title":"Toward deciphering the mechanistic role of variations in the Rep1 repeat site in the transcription regulation of SNCA gene","volume":"19","author":"Afek","year":"2018","journal-title":"Neurogenetics"},{"key":"10.1016\/j.ymthe.2021.01.001_bib95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.irn.2017.01.009","article-title":"Genetics of Parkinson\u2019s Disease: Genotype-Phenotype Correlations","volume":"132","author":"Koros","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib96","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.01.001_bib97","doi-asserted-by":"crossref","first-page":"e24834","DOI":"10.1371\/journal.pone.0024834","article-title":"Neuropathology in mice expressing mouse alpha-synuclein","volume":"6","author":"Rieker","year":"2011","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2021.01.001_bib98","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance","volume":"139","author":"Hernandez","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib99","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2010.07.010","article-title":"Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice","volume":"40","author":"Melrose","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fnins.2015.00503","article-title":"Evaluation of Models of Parkinson\u2019s Disease","volume":"9","author":"Jagmag","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2004.07.001","article-title":"Alpha-synuclein and transgenic mouse models","volume":"17","author":"Fernagut","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib102","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1602\/neurorx.2.3.484","article-title":"Toxin-induced models of Parkinson\u2019s disease","volume":"2","author":"Bov\u00e9","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ymthe.2021.01.001_bib103","doi-asserted-by":"crossref","DOI":"10.1177\/1759091418777438","article-title":"Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment","volume":"10","author":"Zeng","year":"2018","journal-title":"ASN Neuro"},{"key":"10.1016\/j.ymthe.2021.01.001_bib104","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2021.01.001_bib106","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-12-800149-3.00003-2","article-title":"Methods for gene transfer to the central nervous system","volume":"87","author":"Kantor","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib109","doi-asserted-by":"crossref","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/78078","article-title":"Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein","volume":"25","author":"Lewis","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib111","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0002-9440(10)63124-0","article-title":"Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau","volume":"164","author":"Klein","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib112","doi-asserted-by":"crossref","first-page":"e7280","DOI":"10.1371\/journal.pone.0007280","article-title":"AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice","volume":"4","author":"Jaworski","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib113","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-1-4939-3271-9_25","article-title":"Gene Therapy Models of Alzheimer\u2019s Disease and Other Dementias","volume":"1382","author":"Combs","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib114","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/NEN.0000000000000006","article-title":"A rapid gene delivery-based mouse model for early-stage Alzheimer disease-type tauopathy","volume":"72","author":"Siman","year":"2013","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib115","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/S0960-894X(01)00332-8","article-title":"In\u00a0vitro and In\u00a0vivo inhibition of LPS-stimulated tumor necrosis factor-alpha secretion by the gallotannin beta-D-pentagalloylglucose","volume":"11","author":"Feldman","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2021.01.001_bib116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1326-2-11","article-title":"Novel rat Alzheimer\u2019s disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels","volume":"2","author":"Lawlor","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2021.01.001_bib117","doi-asserted-by":"crossref","first-page":"e59166","DOI":"10.1371\/journal.pone.0059166","article-title":"Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum","volume":"8","author":"Drummond","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib118","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.expneurol.2012.02.011","article-title":"Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models","volume":"235","author":"Herman","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib119","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jnc.12630","article-title":"Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis","volume":"129","author":"Hebron","year":"2014","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib120","first-page":"209","article-title":"The Role of Upregulated APOE in Alzheimer\u2019s Disease Etiology","volume":"6","author":"Gottschalk","year":"2016","journal-title":"J.\u00a0Alzheimers Dis. Parkinsonism"},{"key":"10.1016\/j.ymthe.2021.01.001_bib121","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13024-015-0001-3","article-title":"Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice","volume":"10","author":"Hu","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2021.01.001_bib122","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","article-title":"Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models","volume":"44","author":"Zhao","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2021.01.001_bib123","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","article-title":"Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system","volume":"22","author":"Kirik","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib124","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1089\/10430340252837206","article-title":"Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra","volume":"13","author":"Klein","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.01.001_bib125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1750-3639.2003.tb00035.x","article-title":"Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein","volume":"13","author":"Lauwers","year":"2003","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib126","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1073\/pnas.152339799","article-title":"alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson\u2019s disease","volume":"99","author":"Lo Bianco","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib127","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","article-title":"Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy","volume":"29","author":"Chung","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neurobiolaging.2005.12.005","article-title":"Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression","volume":"28","author":"Lauwers","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymthe.2021.01.001_bib129","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.nbd.2006.04.007","article-title":"Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression","volume":"23","author":"Maingay","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib130","first-page":"281","article-title":"Alpha-synuclein overexpression model","author":"Mochizuki","year":"2006","journal-title":"J.\u00a0Neural Transm. Suppl."},{"key":"10.1016\/j.ymthe.2021.01.001_bib131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1471-4159.2004.02728.x","article-title":"Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson\u2019s disease","volume":"91","author":"Yamada","year":"2004","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib132","first-page":"872","article-title":"Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson\u2019s disease","volume":"18","author":"Azeredo da Silveira","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib133","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/brain\/awl382","article-title":"Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain","volume":"130","author":"Eslamboli","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2021.01.001_bib134","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1073\/pnas.0711053105","article-title":"The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease","volume":"105","author":"Gorbatyuk","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib135","doi-asserted-by":"crossref","first-page":"e17698","DOI":"10.1371\/journal.pone.0017698","article-title":"Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson\u2019s disease produced by decreasing doses of alpha-synuclein","volume":"6","author":"Koprich","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib136","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2009.06010.x","article-title":"Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system","volume":"109","author":"McFarland","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2021.01.001_bib137","doi-asserted-by":"crossref","first-page":"e8784","DOI":"10.1371\/journal.pone.0008784","article-title":"Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson\u2019s disease","volume":"5","author":"Sanchez-Guajardo","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib138","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/NEN.0b013e3181a24b53","article-title":"Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease","volume":"68","author":"McFarland","year":"2009","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib139","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In\u00a0vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.01.001_bib140","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.01.001_bib141","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2012.08.020","article-title":"Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984","volume":"425","author":"Glenner","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib142","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib143","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","article-title":"Role of genes and environments for explaining Alzheimer disease","volume":"63","author":"Gatz","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ymthe.2021.01.001_bib144","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/hmg\/ddy355","article-title":"Multiplication of the SNCA locus exacerbates neuronal nuclear aging","volume":"28","author":"Tagliafierro","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.stem.2015.02.004","article-title":"Elucidating molecular phenotypes caused by the SORL1 Alzheimer\u2019s disease genetic risk factor using human induced pluripotent stem cells","volume":"16","author":"Young","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib146","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrg2937","article-title":"Methods for making induced pluripotent stem cells: reprogramming \u00e0 la carte","volume":"12","author":"Gonz\u00e1lez","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib147","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/nbt.1503","article-title":"Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes","volume":"26","author":"Aasen","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib148","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1182\/blood-2009-02-204800","article-title":"Generation of induced pluripotent stem cells from human blood","volume":"113","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.01.001_bib149","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/7651_2014_139","article-title":"Generation of iPS Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors","volume":"1357","author":"Su","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12015-015-9622-8","article-title":"Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming Strategies","volume":"12","author":"Brouwer","year":"2016","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.ymthe.2021.01.001_bib151","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-62703-348-0_3","article-title":"A review of the methods for human iPSC derivation","volume":"997","author":"Malik","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib152","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature07677","article-title":"Induced pluripotent stem cells from a spinal muscular atrophy patient","volume":"457","author":"Ebert","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib153","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fncel.2019.00026","article-title":"Grafted Human iPSC-Derived Neural Progenitor Cells Express Integrins and Extend Long-Distance Axons Within the Developing Corticospinal Tract","volume":"13","author":"Forbes","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib154","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13041-016-0265-8","article-title":"Pathological classification of human iPSC-derived neural stem\/progenitor cells towards safety assessment of transplantation therapy for CNS diseases","volume":"9","author":"Sugai","year":"2016","journal-title":"Mol. Brain"},{"issue":"R2","key":"10.1016\/j.ymthe.2021.01.001_bib155","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddy186","article-title":"Drug screening for human genetic diseases using iPSC models","volume":"27","author":"Elitt","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib156","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.scr.2015.10.014","article-title":"Rapid generation of sub-type, region-specific neurons and neural networks from human pluripotent stem cell-derived neurospheres","volume":"15","author":"Begum","year":"2015","journal-title":"Stem Cell Res. (Amst.)"},{"key":"10.1016\/j.ymthe.2021.01.001_bib157","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1089\/scd.2013.0511","article-title":"Induced pluripotent stem cells from familial Alzheimer\u2019s disease patients differentiate into mature neurons with amyloidogenic properties","volume":"23","author":"Mahairaki","year":"2014","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.ymthe.2021.01.001_bib158","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","article-title":"Rapid single-step induction of functional neurons from human pluripotent stem cells","volume":"78","author":"Zhang","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib159","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/stem.1334","article-title":"Efficient generation of astrocytes from human pluripotent stem cells in defined conditions","volume":"31","author":"Shaltouki","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2021.01.001_bib160","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.stemcr.2017.06.018","article-title":"An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells","volume":"9","author":"Tcw","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymthe.2021.01.001_bib161","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","article-title":"APOE \u03b54\/\u03b54 diminishes neurotrophic function of human iPSC-derived astrocytes","volume":"26","author":"Zhao","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib162","doi-asserted-by":"crossref","first-page":"E2243","DOI":"10.1073\/pnas.1614412114","article-title":"Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors","volume":"114","author":"Ehrlich","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.01.001_bib163","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.stem.2012.12.002","article-title":"Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination","volume":"12","author":"Wang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib164","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neuron.2017.03.042","article-title":"iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases","volume":"94","author":"Abud","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib165","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/nm.4189","article-title":"Efficient derivation of microglia-like cells from human pluripotent stem cells","volume":"22","author":"Muffat","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib166","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nn.4534","article-title":"Differentiation of human and murine induced pluripotent stem cells to microglia-like cells","volume":"20","author":"Pandya","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib167","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib168","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1093\/hmg\/ddr394","article-title":"Modeling familial Alzheimer\u2019s disease with induced pluripotent stem cells","volume":"20","author":"Yagi","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib169","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","article-title":"Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells","volume":"482","author":"Israel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","article-title":"LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress","volume":"8","author":"Nguyen","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib171","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/emmm.201200215","article-title":"Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson\u2019s disease","volume":"4","author":"S\u00e1nchez-Dan\u00e9s","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib172","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-6606-5-35","article-title":"Mitochondrial dysfunction associated with increased oxidative stress and \u03b1-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue","volume":"5","author":"Imaizumi","year":"2012","journal-title":"Mol. Brain"},{"key":"10.1016\/j.ymthe.2021.01.001_bib173","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ncomms1453","article-title":"Parkinson\u2019s disease induced pluripotent stem cells with triplication of the \u03b1-synuclein locus","volume":"2","author":"Devine","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib174","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","article-title":"Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression","volume":"12","author":"Reinhardt","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib175","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1523\/JNEUROSCI.4441-10.2011","article-title":"Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells","volume":"31","author":"Seibler","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib176","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","article-title":"Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations","volume":"146","author":"Soldner","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib177","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib178","doi-asserted-by":"crossref","first-page":"165ra162","DOI":"10.1126\/scitranslmed.3004108","article-title":"Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy","volume":"4","author":"Corti","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib179","doi-asserted-by":"crossref","first-page":"42030","DOI":"10.18632\/oncotarget.14925","article-title":"Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2021.01.001_bib180","doi-asserted-by":"crossref","first-page":"eaat5847","DOI":"10.1126\/sciadv.aat5847","article-title":"Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons","volume":"4","author":"Osaki","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2021.01.001_bib181","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","article-title":"Modeling Alzheimer\u2019s disease with iPSCs reveals stress phenotypes associated with intracellular A\u03b2 and differential drug responsiveness","volume":"12","author":"Kondo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib182","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","article-title":"ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib183","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","article-title":"APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer\u2019s Disease Phenotypes in Human iPSC-Derived Brain Cell Types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib184","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.stemcr.2017.12.021","article-title":"Astrocytes Attenuate Mitochondrial Dysfunctions in Human Dopaminergic Neurons Derived from iPSC","volume":"10","author":"Du","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymthe.2021.01.001_bib185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2018.12.011","article-title":"Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson\u2019s Disease","volume":"12","author":"di Domenico","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymthe.2021.01.001_bib186","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/j.celrep.2016.12.001","article-title":"Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain","volume":"17","author":"Luo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2021.01.001_bib187","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.stem.2017.07.007","article-title":"Fusion of Regionally Specified hPSC-Derived Organoids Models Human Brain Development and Interneuron Migration","volume":"21","author":"Xiang","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib188","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature12517","article-title":"Cerebral organoids model human brain development and microcephaly","volume":"501","author":"Lancaster","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib189","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.3415","article-title":"Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture","volume":"12","author":"Pa\u015fca","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2021.01.001_bib190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuron.2017.07.035","article-title":"Human Astrocyte Maturation Captured in 3D Cerebral Cortical Spheroids Derived from Pluripotent Stem Cells","volume":"95","author":"Sloan","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.01.001_bib191","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1038\/s41380-018-0229-8","article-title":"Modeling amyloid beta and tau pathology in human cerebral organoids","volume":"23","author":"Gonzalez","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ymthe.2021.01.001_bib192","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1038\/s41467-020-19264-0","article-title":"APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer\u2019s disease patient iPSC-derived cerebral organoids","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib193","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41531-019-0078-4","article-title":"Modeling Parkinson\u2019s disease in midbrain-like organoids","volume":"5","author":"Smits","year":"2019","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib194","first-page":"1800927","article-title":"3D Cultures of Parkinson\u2019s Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing","volume":"6","author":"Bolognin","year":"2018","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ymthe.2021.01.001_bib195","doi-asserted-by":"crossref","first-page":"dev166074","DOI":"10.1242\/dev.166074","article-title":"Brain organoids: advances, applications and challenges","volume":"146","author":"Qian","year":"2019","journal-title":"Development"},{"key":"10.1016\/j.ymthe.2021.01.001_bib196","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41586-019-1289-x","article-title":"Individual brain organoids reproducibly form cell diversity of the human cerebral cortex","volume":"570","author":"Velasco","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib197","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13024-018-0258-4","article-title":"2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling","volume":"13","author":"Centeno","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2021.01.001_bib198","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41593-018-0175-4","article-title":"A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer\u2019s disease","volume":"21","author":"Park","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib199","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41467-017-02636-4","article-title":"Engineering human pluripotent stem cells into a functional skeletal muscle tissue","volume":"9","author":"Rao","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib200","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41591-020-0886-4","article-title":"Reconstruction of the human blood-brain barrier in\u00a0vitro reveals a pathogenic mechanism of APOE4 in pericytes","volume":"26","author":"Blanchard","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib201","doi-asserted-by":"crossref","first-page":"180177","DOI":"10.1098\/rsob.180177","article-title":"Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease","volume":"9","author":"Wu","year":"2019","journal-title":"Open Biol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib202","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fcell.2020.00328","article-title":"In\u00a0vitro Models of Neurodegenerative Diseases","volume":"8","author":"Slanzi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib203","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12929-019-0578-x","article-title":"Human iPSC banking: barriers and opportunities","volume":"26","author":"Huang","year":"2019","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib204","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-genet-120417-031534","article-title":"Aging in a Dish: iPSC-Derived and Directly Induced Neurons for Studying Brain Aging and Age-Related Neurodegenerative Diseases","volume":"52","author":"Mertens","year":"2018","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib205","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.stemcr.2018.08.019","article-title":"Fast Generation of Functional Subtype Astrocytes from Human Pluripotent Stem Cells","volume":"11","author":"Li","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymthe.2021.01.001_bib206","doi-asserted-by":"crossref","first-page":"135028","DOI":"10.1016\/j.neulet.2020.135028","article-title":"Characterization of human iPSC-derived astrocytes with potential for disease modeling and drug discovery","volume":"731","author":"Soubannier","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2021.01.001_bib207","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13024-018-0297-x","article-title":"Development and validation of a simplified method to generate human microglia from pluripotent stem cells","volume":"13","author":"McQuade","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymthe.2021.01.001_bib208","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1038\/s41467-020-17165-w","article-title":"Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson\u2019s disease","volume":"11","author":"Doi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib209","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1113\/JP270655","article-title":"Improving and accelerating the differentiation and functional maturation of human stem cell-derived neurons: role of extracellular calcium and GABA","volume":"594","author":"Kemp","year":"2016","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/cells8050403","article-title":"Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications","volume":"8","author":"Doss","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2021.01.001_bib211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41467-019-13830-x","article-title":"Genetic aberrations in iPSCs are introduced by a transient G1\/S cell cycle checkpoint deficiency","volume":"11","author":"Araki","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib212","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib213","doi-asserted-by":"crossref","first-page":"dmm042317","DOI":"10.1242\/dmm.042317","article-title":"Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility","volume":"13","author":"Volpato","year":"2020","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2021.01.001_bib214","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fgene.2017.00058","article-title":"Amyloid \u03b2 Modification: A Key to the Sporadic Alzheimer\u2019s Disease?","volume":"8","author":"Barykin","year":"2017","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2021.01.001_bib215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","article-title":"Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells","volume":"6","author":"Tran","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib216","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","article-title":"Oxidative stress and cellular pathologies in Parkinson\u2019s disease","volume":"10","author":"Puspita","year":"2017","journal-title":"Mol. Brain"},{"key":"10.1016\/j.ymthe.2021.01.001_bib217","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.scr.2018.01.019","article-title":"Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-\u03b2 and tau pathology in iPSC-derived neurons from sporadic Alzheimer\u2019s disease patients","volume":"27","author":"Birnbaum","year":"2018","journal-title":"Stem Cell Res. (Amst.)"},{"key":"10.1016\/j.ymthe.2021.01.001_bib218","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.celrep.2019.01.023","article-title":"REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer\u2019s Disease","volume":"26","author":"Meyer","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2021.01.001_bib219","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1101\/gr.141945.112","article-title":"Pluripotent stem cells escape from senescence-associated DNA methylation changes","volume":"23","author":"Koch","year":"2013","journal-title":"Genome Res."},{"key":"10.1016\/j.ymthe.2021.01.001_bib220","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.stem.2009.11.009","article-title":"Technical challenges in using human induced pluripotent stem cells to model disease","volume":"5","author":"Saha","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib221","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.stem.2013.11.006","article-title":"Human iPSC-based modeling of late-onset disease via progerin-induced aging","volume":"13","author":"Miller","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib222","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.celrep.2016.09.062","article-title":"Generating Late-Onset Human iPSC-Based Disease Models by Inducing Neuronal Age-Related Phenotypes through Telomerase Manipulation","volume":"17","author":"Vera","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2021.01.001_bib223","doi-asserted-by":"crossref","first-page":"141ra90","DOI":"10.1126\/scitranslmed.3003985","article-title":"Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson\u2019s disease","volume":"4","author":"Cooper","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib224","doi-asserted-by":"crossref","first-page":"e26159","DOI":"10.1371\/journal.pone.0026159","article-title":"SNCA triplication Parkinson\u2019s patient\u2019s iPSC-derived DA neurons accumulate \u03b1-synuclein and are susceptible to oxidative stress","volume":"6","author":"Byers","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.01.001_bib225","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cell.2011.05.036","article-title":"Cell fate plug and play: direct reprogramming and induced pluripotency","volume":"145","author":"Chambers","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib226","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nature08797","article-title":"Direct conversion of fibroblasts to functional neurons by defined factors","volume":"463","author":"Vierbuchen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib227","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/1535370215577585","article-title":"Overcoming the hurdles for a reproducible generation of human functionally mature reprogrammed neurons","volume":"240","author":"Broccoli","year":"2015","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.ymthe.2021.01.001_bib228","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1172\/JCI74664","article-title":"Remote control of induced dopaminergic neurons in parkinsonian rats","volume":"124","author":"Dell\u2019Anno","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.01.001_bib229","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nbt.3835","article-title":"Induction of functional dopamine neurons from human astrocytes in\u00a0vitro and mouse astrocytes in a Parkinson\u2019s disease model","volume":"35","author":"Rivetti di Val Cervo","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib230","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2021.01.001_bib231","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","article-title":"Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference","volume":"9","author":"Young","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib232","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.celrep.2017.10.109","article-title":"iPSC-Based Compound Screening and In\u00a0Vitro Trials Identify a Synergistic Anti-amyloid \u03b2 Combination for Alzheimer\u2019s Disease","volume":"21","author":"Kondo","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2021.01.001_bib233","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2013.10.013","article-title":"LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson\u2019s disease patients: reversal by gene correction","volume":"62","author":"Sanders","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2021.01.001_bib234","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(12)60028-2","article-title":"Embryonic stem cell trials for macular degeneration: a preliminary report","volume":"379","author":"Schwartz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.01.001_bib235","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.oret.2019.04.021","article-title":"Evaluation of Transplanted Autologous Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in Exudative Age-Related Macular Degeneration","volume":"3","author":"Takagi","year":"2019","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.ymthe.2021.01.001_bib236","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/stem.1083","article-title":"Treatment of a mouse model of spinal cord injury by transplantation of human induced pluripotent stem cell-derived long-term self-renewing neuroepithelial-like stem cells","volume":"30","author":"Fujimoto","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2021.01.001_bib237","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1172\/JCI130767","article-title":"Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson\u2019s disease models","volume":"130","author":"Song","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.01.001_bib238","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1038\/s41467-019-12324-0","article-title":"MHC matching fails to prevent long-term rejection of iPSC-derived neurons in non-human primates","volume":"10","author":"Aron Badin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.01.001_bib239","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","article-title":"Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration","volume":"376","author":"Mandai","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.01.001_bib240","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib241","doi-asserted-by":"crossref","first-page":"e010239","DOI":"10.1161\/JAHA.118.010239","article-title":"Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy","volume":"7","author":"Mattapally","year":"2018","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2021.01.001_bib242","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature00900","article-title":"Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson\u2019s disease","volume":"418","author":"Kim","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.01.001_bib243","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nn1402","article-title":"Directed differentiation of telencephalic precursors from embryonic stem cells","volume":"8","author":"Watanabe","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2021.01.001_bib244","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.copbio.2007.10.006","article-title":"Therapeutic applications of oligodendrocyte precursors derived from human embryonic stem cells","volume":"18","author":"Sharp","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.01.001_bib245","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.stem.2018.10.009","article-title":"20 Years of Human Pluripotent Stem Cell Research: It All Started with Five Lines","volume":"23","author":"Ludwig","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.01.001_bib246","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.2013.282542","article-title":"Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012","volume":"311","author":"Sacks","year":"2014","journal-title":"JAMA"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:01:38Z","timestamp":1761501698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":246,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1525001621000010"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}